Pomerantz LLP Files Class Action Against GeneDx Holdings Corp. (NASDAQ: WGS), Warns of Upcoming Deadlines
Pomerantz LLP, the New York-based plaintiff securities law firm, has announced the filing of a class action lawsuit against GeneDx Holdings Corp. (NASDAQ: WGS), the genomic diagnostics company. The firm is alerting investors who recorded losses on WGS holdings and flagging approaching legal deadlines for participation in the case.
Pomerantz LLP, the New York-based plaintiff securities law firm, has announced the filing of a class action lawsuit against GeneDx Holdings Corp. (NASDAQ: WGS), the genomic diagnostics company. The firm is alerting investors who recorded losses on WGS holdings and flagging approaching legal deadlines for participation in the case.
The Lawsuit
Pomerantz LLP, which operates under the Pomerantz Law Firm name in investor-facing communications, confirmed the class action was filed against GeneDx Holdings Corp., traded on the Nasdaq exchange under the ticker WGS. The announcement, issued from New York on July 2, 2026, did not disclose the specific allegations underpinning the complaint, the dollar value of damages sought, or the precise deadline dates in the source material available at publication.
Class action securities cases of this type typically consolidate claims from multiple investors who allege they suffered losses tied to the same set of circumstances. The source does not specify the proposed class period or the nature of the alleged harm.
What Affected Investors Should Know
Pomerantz has directed investors with losses in GeneDx Holdings Corp. to contact attorney Danielle Peyton directly. She can be reached by email at [email protected] or by telephone at 646-581-9980. The firm's announcement emphasizes that deadlines are approaching, which in securities class actions typically refer to the lead plaintiff motion deadline set by the court — after which investors may lose certain rights to take a more active role in directing the litigation.
Investors who believe they may qualify for inclusion in the class are advised to act before those deadlines pass. The source does not specify the exact dates.
GeneDx Holdings Corp. at a Glance
GeneDx Holdings Corp. trades on the Nasdaq under the symbol WGS. The company operates in the genomic sequencing and diagnostics space. The source contains no detail on the company's current share price, market capitalization, or any operational developments tied to the litigation.
Pomerantz LLP did not respond to a request for additional comment at the time of publication. GeneDx Holdings Corp. had not issued a public response to the lawsuit announcement based on materials available at the time this article was written.
Related reading
Filed by the macro desk of MarketPR on July 3, 2026. Source: MarketPR. Indicative figures are not investment advice.